GlassScriptPhysician profile
James L Vosberg
NPI 1235132747
$4,162.05
in general payments reported to CMS, 2019-2025
37 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $520 · 2021: $538 · 2022: $584 · 2023: $772 · 2024: $679 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $976.63 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $548.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $399.47 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.77 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $290.17 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Viiv Healthcare Company | $259.91 | 2022-2025 | Apretude |
| Astrazeneca Pharmaceuticals LP | $146.42 | 2024-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $83.12 | 2020-2021 | |
| Exact Sciences Corporation | $82.96 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $73.38 | 2019-2021 | |
| Eisai INC. | $69.24 | 2020-2021 | |
| Shire North American Group INC | $66.05 | 2019 | |
| Dexcom, INC. | $59.97 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $59.93 | 2022 | |
| Radius Health, INC. | $56.10 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $52.90 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $50.69 | 2022-2024 | Quviviq |
| Pfizer INC. | $48.55 | 2023-2025 | |
| Nevro Corp. | $45.33 | 2019 | |
| Gilead Sciences, INC. | $42.92 | 2023-2025 | |
| Tactile Systems Technology INC | $38.16 | 2025 | Flexitouch Plus, Nimbl |
| Allergan, INC. | $37.30 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $36.51 | 2023-2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $34.86 | 2025 | |
| Amarin Pharma, INC. | $34.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $32.18 | 2021 | |
| Arbor Pharmaceuticals, INC. | $29.41 | 2019 | |
| Alk-Abello, INC | $27.51 | 2024 | Grastek, Ragwitek, Odactra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.71 | 2025 | Jardiance |
| Lundbeck LLC | $20.43 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $19.45 | 2023 | Austedo Xr |
| Genentech USA, INC. | $19.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.28 | 2025 | |
| Glaxosmithkline, LLC. | $17.84 | 2020 | |
| Astellas Pharma US INC | $17.13 | 2019 | |
| Medtronic USA, INC. | $16.74 | 2020 | |
| Esperion Therapeutics, INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vosberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.